Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dynavax Technologies Corporation

DVAX
Current price
13.76 USD -0.06 USD (-0.43%)
Last closed 13.92 USD
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 1 782 509 184 USD
Yield for 12 month +18.52 %
Week
Month
Year
DVAX
21.11.2021 - 28.11.2021

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California. Address: 2100 Powell Street, EmeryVille, CA, United States, 94608

Analytics

WallStreet Target Price

25 USD

P/E ratio

33.6341

Dividend Yield

9.95 %

Current Year

+722 683 000 USD

Last Year

+439 442 000 USD

Current Quarter

+69 514 000 USD

Last Quarter

+60 249 000 USD

Current Year

+460 530 000 USD

Last Year

+265 870 000 USD

Current Quarter

+56 285 000 USD

Last Quarter

+46 712 000 USD

Key Figures DVAX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 79 560 000 USD
Operating Margin TTM 8.79 %
PE Ratio 33.6341
Return On Assets TTM 4.78 %
PEG Ratio
Return On Equity TTM 11.06 %
Wall Street Target Price 25 USD
Revenue TTM 361 180 000 USD
Book Value 4.68 USD
Revenue Per Share TTM 2.82 USD
Dividend Share
Quarterly Revenue Growth YOY -58.6 %
Dividend Yield 9.95 %
Gross Profit TTM 448 218 000 USD
Earnings Share 0.41 USD
Diluted Eps TTM 0.41 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY -76.5 %
Profit Margin 16.92 %

Dividend Analytics DVAX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History DVAX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 9.95 %
Last Split Factor 1:10
Payout Ratio
Last Split Date 10.11.2014
Dividend Date

Stock Valuation DVAX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 33.6341
Forward PE 22.9885
Enterprise Value Revenue 3.6499
Price Sales TTM 4.9352
Enterprise Value EBITDA 17.3228
Price Book MRQ 2.9446

Financials DVAX

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators DVAX

For 52 weeks

9.42 USD 15.15 USD
50 Day MA 14.03 USD
Shares Short Prior Month 13 853 352
200 Day MA 12.6 USD
Short Ratio 8.22
Shares Short 13 856 684
Short Percent 13.08 %